Related Experiment Video
Updated: Jan 13, 2026
Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
Published on: February 21, 2019
Comparative Efficacy of CK2 Inhibitors CX-4945 and SGC-CK2-2 on CK2 Signaling
Francesca Noventa1, Rina Venerando2, Valentina Bosello Travain2
1Department of Biomedical Sciences, University of Padova, Via U. Bassi 58/B, 35131 Padova, Italy.
Abstract:
The pleiotropic kinase CK2 plays a crucial role in numerous cellular processes and is frequently deregulated in human diseases. Specifically, elevated CK2 expression and/or activity have been observed in human cancers, thus rendering its inhibition a promising pharmacological strategy for treating malignancies. The most widely used CK2 inhibitor, CX-4945 (Silmitarsetib), was developed by Cylene Pharmaceuticals in 2010. It has been tested in clinical trials for various cancers and, more recently, as a potential therapy for COVID-19 patients. However, it has been demonstrated that CX-4945's specificity is limited, as CX-4945 also inhibits other kinases beyond CK2. A recently developed derivative of CX-4945, SGC-CK2-2, has demonstrated enhanced specificity compared with CX-4945, albeit with reduced potency. In this study, we conducted a detailed analysis of the effects of SGC-CK2-2 in two cancer cell lines, comparing its efficacy with CX-4945 in inhibiting CK2 signaling and in cell death induction. The findings of this study demonstrate the differential sensitivity of CK2 phospho-substrates to these inhibitors, thus indicating that complete inhibition of a single phosphosite, such as S129 Akt, is insufficient to fully suppress CK2 signaling. Furthermore, the results suggest that partial CK2 inhibition with the suppression of the most sensitive phosphosites does not significantly impact cell viability, while a near-complete suppression of CK2 signaling affects cell viability and leads to cell death induction.
Insights
The protein kinase CK2 is crucial in cancer. While CX-4945 inhibits CK2, its derivative SGC-CK2-2 shows better specificity. Complete CK2 inhibition is needed to affect cancer cell viability and induce cell death.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Biology
Background:
- Protein kinase CK2 (CK2) is a pleiotropic enzyme implicated in numerous cellular functions.
- Aberrant CK2 activity is linked to human diseases, particularly cancers, making CK2 inhibition a therapeutic strategy.
- CX-4945 (Silmitarsetib) is a widely used CK2 inhibitor, but exhibits limited specificity, inhibiting other kinases.
- SGC-CK2-2, a CX-4945 derivative, offers improved specificity but reduced potency.
Purpose of the Study:
- To compare the efficacy of SGC-CK2-2 and CX-4945 in inhibiting CK2 signaling and inducing cell death in cancer cell lines.
- To analyze the differential sensitivity of CK2 phospho-substrates to these inhibitors.
- To determine the relationship between the extent of CK2 inhibition and its impact on cancer cell viability.
Main Methods:
- Utilized two cancer cell lines for comparative analysis.
- Assessed the inhibition of CK2 signaling pathways by SGC-CK2-2 and CX-4945.
- Evaluated the induction of cell death in response to inhibitor treatment.
- Analyzed the phosphorylation status of CK2 substrates.
Main Results:
- Demonstrated differential sensitivity of CK2 phospho-substrates to SGC-CK2-2 and CX-4945.
- Showed that complete inhibition of a single phosphosite (e.g., S129 Akt) is insufficient for full CK2 signaling suppression.
- Found that partial CK2 inhibition does not significantly affect cell viability.
- Observed that near-complete CK2 signaling suppression leads to reduced cell viability and cell death induction.
Conclusions:
- The degree of CK2 inhibition is critical for its anti-cancer effects.
- Targeting specific phosphosites alone may not be sufficient for effective CK2-targeted cancer therapy.
- Near-complete suppression of CK2 signaling is required to impact cancer cell viability and induce cell death, highlighting the importance of inhibitor potency and specificity.
More Related Videos
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
08:49Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
